In short
Enasidenib Mesylate, also known as Idhifa, is being studied in several clinical trials as a potential treatment for acute myeloid leukemia (AML), particularly in cases with IDH2 gene mutations. These trials are exploring its use alone and in combination with other drugs for both newly diagnosed and relapsed/refractory AML patients. The studies aim to evaluate the safety, efficacy, and optimal dosing of enasidenib-based regimens in various AML patient populations.
At a glance
- Patient Populations
- Newly diagnosed AML, Relapsed/Refractory AML, Post-transplant AML
- Enasidenib Combinations
- Monotherapy, With azacitidine, With venetoclax and decitabine, With glasdegib
- Key Outcomes Measured
- Safety, Efficacy, Remission rates, Overall survival, Pharmacokinetics
- Biomarker Assessments
- IDH2 mutation clearance, Minimal residual disease, Leukemia stem cell burden
- Administration Route
- Oral, daily dosing
- Trial Phases
- Phase 1b, Phase 2
What is Enasidenib?
Enasidenib Mesylate, also known by its brand name Idhifa, is a medication used in the treatment of certain types of blood cancers. It belongs to a class of drugs called targeted therapies, which are designed to attack specific cancer cells while minimizing damage to healthy cells. Enasidenib is also referred to by several other names, including AG-221 Mesylate, CC-90007, and Enasidenib Methanesulfonate.
How Does Enasidenib Work?
Enasidenib works by targeting a specific genetic mutation found in some cancer cells. This mutation affects a protein called IDH2 (isocitrate dehydrogenase-2). In patients with this mutation, the IDH2 protein doesn't function correctly, leading to the growth of cancer cells. Enasidenib blocks the abnormal IDH2 protein, which may help stop or slow down the growth of cancer cells.
What Conditions Does Enasidenib Treat?
Enasidenib is primarily used to treat a type of blood cancer called Acute Myeloid Leukemia (AML) in patients who have a specific IDH2 mutation. It's particularly useful in the following situations:
- Relapsed or Refractory AML: This refers to AML that has either come back after treatment (relapsed) or hasn't responded well to initial treatments (refractory).
- AML in patients who have undergone stem cell transplantation: Enasidenib is being studied as a maintenance therapy for patients who have received a donor stem cell transplant.
- Newly diagnosed AML: Some studies are exploring the use of Enasidenib in combination with other drugs for patients newly diagnosed with AML.
Current Clinical Trials
Several clinical trials are currently underway to further investigate the effectiveness of Enasidenib in various scenarios:
- As a maintenance therapy after stem cell transplantation.
- In combination with other drugs like Cobimetinib for relapsed or refractory AML.
- Combined with Azacitidine for relapsed or refractory AML.
- As part of a combination therapy with CPX-351 (a chemotherapy drug) for relapsed AML.
- In a study comparing different treatment combinations for relapsed AML after stem cell transplantation.
How is Enasidenib Administered?
Enasidenib is typically taken orally (by mouth) once daily. The exact dosage and duration of treatment can vary depending on the specific condition being treated and the individual patient's response. In most clinical trials, Enasidenib is given in cycles, with each cycle lasting 28 days.
Potential Side Effects
As with any medication, Enasidenib can cause side effects. The most common and serious side effects are still being studied in clinical trials. One particular side effect that doctors watch for is called IDH-inhibitor related differentiation syndrome (IDH-DS), which can cause fever, difficulty breathing, and other symptoms. It's important for patients to report any unusual symptoms to their healthcare provider promptly.
Combination Therapies
Researchers are exploring the use of Enasidenib in combination with other cancer treatments to potentially improve outcomes for patients. Some of these combinations include:
- Enasidenib with Cobimetinib (another targeted therapy).
- Enasidenib with Azacitidine (a chemotherapy drug).
- Enasidenib with CPX-351 (a combination chemotherapy drug).
- Enasidenib with Glasdegib (another targeted therapy).
These combination therapies are being studied to determine if they can provide better results than using Enasidenib alone.